Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Targeted scan detects hidden multiple myeloma missed by standard imaging (opens in a new tab)

medicalxpress.com · 2026-11-03

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Also referencedpresented as the new finding

    Phase 2 trial of 89Zr-daratumumab for CD38-targeted immunoPET of multiple myeloma: comparison with 18F-FDG and pathology

    Publisher (opens in a new tab)
The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedA targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedThe study was a phase 2 clinical trial led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and was published in Radiology.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe researchers enrolled 60 patients with multiple myeloma who underwent both a standard glucose-based PET/CT scan and the antibody-based immunoPET scan.View evidenceHide evidence

As stated60 patients

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedMore than 10% of the patients showed disease signals only on the immunoPET scans, and follow-up biopsies confirmed those signals were active myeloma disease missed by the traditional PET/CT scans.View evidenceHide evidence

As statedmore than 10%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedImmunoPET uncovered disease in 17 patients (28%) that standard PET/CT missed, while the reverse occurred in 13 patients (22%), showing that no single imaging test identified every case of myeloma.View evidenceHide evidence

As stated17 patients (28%); 13 patients (22%)

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe article says the current scan still has limitations, including that it takes about a week for the antibody to travel through the body and attach to cancer cells, and that next-generation smaller fragments could enable a same-day test.View evidenceHide evidence

As statedabout a week

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Explore all search results